GlassScriptPhysician profile
Nikolaus P King
NPI 1780279448
$743.95
in general payments reported to CMS, 2019-2025
15 companies · $467 in 2025
The $467 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2023: $106 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.18 | 2025 | |
| Paratek Pharmaceuticals, INC. | $105.53 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $93.90 | 2025 | Biktarvy |
| Melinta Therapeutics, LLC | $61.90 | 2025 | Rezzayo |
| Mallinckrodt Hospital Products INC. | $60.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.58 | 2021 | |
| La Jolla Pharmaceutical Company | $37.53 | 2025 | Zevtera, Xacduro |
| Neurocrine Biosciences, INC. | $25.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.19 | 2021 | |
| Viiv Healthcare Company | $22.96 | 2025 | Rukobia |
| Insmed, INC. | $21.95 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $20.94 | 2025 | Capvaxive, Pifeltro |
| Cormedix INC. | $20.22 | 2025 | Defencath |
| Smith+Nephew, INC. | $15.52 | 2025 | Collagenase Santyl |
| Fresenius USA Marketing, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolaus King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.